Last reviewed · How we verify
TRx0037
At a glance
| Generic name | TRx0037 |
|---|---|
| Sponsor | TauRx Therapeutics Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Multiple Dose Study of TRx0037 (PHASE1)
- Comparative Bioavailability in Healthy Elderly Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRx0037 CI brief — competitive landscape report
- TRx0037 updates RSS · CI watch RSS
- TauRx Therapeutics Ltd portfolio CI